These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 1512327

  • 1. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M.
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [Abstract] [Full Text] [Related]

  • 2. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
    Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, Verstraete M.
    Circulation; 1992 Mar; 85(3):928-34. PubMed ID: 1537129
    [Abstract] [Full Text] [Related]

  • 3. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM.
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [Abstract] [Full Text] [Related]

  • 4. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
    Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL.
    Am J Cardiol; 1990 Dec 15; 66(20):1412-7. PubMed ID: 2123602
    [Abstract] [Full Text] [Related]

  • 5. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
    Zeymer U, von Essen R, Tebbe U, Niederer W, Mäurer W, Vogt A, Neuhaus KL.
    Am J Cardiol; 1995 Nov 15; 76(14):997-1001. PubMed ID: 7484879
    [Abstract] [Full Text] [Related]

  • 6. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C, Nordt TK, Peter K, Smalling RW, Runge MS, Kübler W.
    Am J Cardiol; 1996 Dec 19; 78(12A):16-9. PubMed ID: 8990406
    [Abstract] [Full Text] [Related]

  • 7. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators.
    N Engl J Med; 1993 Nov 25; 329(22):1615-22. PubMed ID: 8232430
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
    Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D.
    Circulation; 1995 Oct 15; 92(8):2044-9. PubMed ID: 7554180
    [Abstract] [Full Text] [Related]

  • 9. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
    de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, López Bescos L, Mueller E, Pfisterer M, Van de Werf F.
    Br Heart J; 1992 Feb 15; 67(2):122-8. PubMed ID: 1540431
    [Abstract] [Full Text] [Related]

  • 10. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL.
    J Am Coll Cardiol; 1994 Apr 15; 23(5):993-1003. PubMed ID: 8144799
    [Abstract] [Full Text] [Related]

  • 11. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Rüdiger Schwarz E, von Loewis P, Rosemeyer P, Hopkins G.
    J Am Coll Cardiol; 1995 Aug 15; 26(2):365-73. PubMed ID: 7608436
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
    Purvis JA, McNeill AJ, Siddiqui RA, Roberts MJ, McClements BM, McEneaney D, Campbell NP, Khan MM, Webb SW, Wilson CM.
    J Am Coll Cardiol; 1994 Jan 15; 23(1):6-10. PubMed ID: 8277097
    [Abstract] [Full Text] [Related]

  • 13. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL, Becker LC, Sorensen SG, Karagounis LA, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM.
    J Am Coll Cardiol; 1992 Oct 15; 20(4):753-66. PubMed ID: 1527286
    [Abstract] [Full Text] [Related]

  • 14. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
    Longridge DJ, Follenfant MJ, Maxwell MP, Ford AJ, Hughes B.
    Cardiovasc Res; 1990 Sep 15; 24(9):697-706. PubMed ID: 2121357
    [Abstract] [Full Text] [Related]

  • 15. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W.
    J Am Coll Cardiol; 1992 Apr 15; 19(5):885-91. PubMed ID: 1552106
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M.
    J Am Coll Cardiol; 1994 Jan 15; 23(1):11-8. PubMed ID: 8277068
    [Abstract] [Full Text] [Related]

  • 17. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
    Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, Randall AM, Knatternud G, Braunwald E.
    Am Heart J; 1996 Mar 15; 131(3):421-33. PubMed ID: 8604620
    [Abstract] [Full Text] [Related]

  • 18. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
    DeWood MA, Kurnik PB, Jolly MK, Jain AC, Khaja F, Gorfinkel HJ, Morris DL, Satler L, LittleJohn J.
    Clin Cardiol; 1993 Apr 15; 16(4):302-10. PubMed ID: 8458110
    [Abstract] [Full Text] [Related]

  • 19. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Rafflenbeul W, Lichtlen PR, Dietz R.
    J Am Coll Cardiol; 1997 Dec 15; 30(7):1611-7. PubMed ID: 9385884
    [Abstract] [Full Text] [Related]

  • 20. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
    Vermeer F, Vahanian A, Fels PW, Besse P, Müller E, Van de Werf F, Fitzgerald D, Darius H, Puel J, Garrigou D, Simoons ML, ARGAMI Study Group.
    J Thromb Thrombolysis; 2000 Dec 15; 10(3):233-40. PubMed ID: 11122543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.